Table 4 Known-group validity by ECOG PS at various timepoints
MDASI-MPM symptomsa | MDASI-MPM interferencea | ||||||
|---|---|---|---|---|---|---|---|
Sample size | Fully active | Restricted active | 95% CI on the difference | Fully active | Restricted active | 95% CI on the difference | |
Baseline | 239 | 1.7 (1.4) | 2.5 (1.7) | −1.2 to − 0.4 | 2.2 (2.1) | 3.8 (2.7) | −2.2 to − 0.9 |
Cycle 2 Day 1 | 208 | 1.7 (1.4) | 2.3 (1.5) | −1.0 to − 0.1 | 2.5 (2.3) | 3.3 (2.5) | −1.4 to − 0.02 |
Cycle 3 Day 1 | 166 | 1.8 (1.4) | 2.3 (1.6) | −1.1 to − 0.06 | 2.6 (2.2) | 3.4 (2.5) | − 1.6 to − 0.03 |
Cycle 4 Day 1 | 135 | 1.9 (1.4) | 2.2 (1.6) | −0.8 to 0.24 | 2.6 (2.3) | 3.2 (2.6) | −1.5 to 0.3 |
Cycle 5 Day 1 | 112 | 2.1 (1.5) | 2.2 (1.6) | −0.7 to 0.5 | 2.9 (2.4) | 3.3 (2.7) | −1.4 to 0.6 |
Safety follow-up | 95 | 2.5 (1.1) | 2.5 (1.6) | −1.1 to 1.0 | 3.9 (1.8) | 3.6 (1.5) | −1.1 to 1.7 |